Cocrystal Pharma Announces Closing of $11.0 Million Registered Direct Offering Priced At-the-Market
Cocrystal Pharma, Inc. (COCP)
NASDAQ:AMEX Investor Relations:
cocrystalpharma.com
Company Research
Source: GlobeNewswire
BOTHELL, WA, Feb. 28, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today the closing of its previously announced registered direct offering with several institutional investors for 8,461,540 shares of its common stock at a purchase price of $1.30 per share, priced at-the-market under Nasdaq rules. The gross proceeds to the Company from the offering totaled approximately $11.0 million, before deducting placement agent fees and offering expenses. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. Cocrystal intends to use the net proceeds for working capital and other general corporate purposes. The shares of common stock described above were offered by Cocrystal Pharma pursuant to a shelf registration statement on Form S-3 (No. 333-220632), which was previously declared effective by the Securities and
Show less
Read more
Impact Snapshot
Event Time:
COCP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COCP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COCP alerts
High impacting Cocrystal Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
COCP
News
- Cocrystal Pharma to Present at the Noble Capital Markets' 21st Emerging Growth Equity Conference [Yahoo! Finance]Yahoo! Finance
- Cocrystal Pharma to Present at the Noble Capital Markets’ 21st Emerging Growth Equity ConferenceGlobeNewswire
- Cocrystal Pharma (NASDAQ:COCP) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs [Yahoo! Finance]Yahoo! Finance
- Cocrystal Pharma GAAP EPS of -$0.19 beats by $0.02 [Seeking Alpha]Seeking Alpha
COCP
Earnings
- 5/15/25 - Beat
COCP
Sec Filings
- 12/1/25 - Form 8-K
- 11/28/25 - Form 4
- 11/25/25 - Form 4
- COCP's page on the SEC website